NSU Newsroom
SharkBytes
Horizons
This version of NSU News has been archived as of February 28, 2019. To search through archived articles, visit nova.edu/search. To access the new version of NSU News, visit news.nova.edu.
This version of SharkBytes has been archived as of February 28, 2019. To search through archived articles, visit nova.edu/search. To access the new version of SharkBytes, visit sharkbytes.nova.edu.
Institute for Neuro-Immune Medicine Hosts Monthly Seminars, Feb. 3
Mutasem Rawas-Qalaji, Ph.D.
The INIM is pleased to host Mutasem Rawas-Qalaji, Ph.D., at the monthly INIM Research Seminar Series on Friday, February 3, 12:00–1:30 p.m. at the Center for Collaborative Research on the 4th floor, room 440.
Qalaji is associate professor of pharmaceutical sciences and director of the Center for Drug Discovery and Development at Nova Southeastern University. The Syrian-Canadian pharmacist earned his pharmacy degree from King Saud University, Saudi Arabia in 1995—and his Ph.D. in pharmaceutics from the University of Manitoba, Canada in 2006. Qalaji has 30 provisional, international, US, European, and Canadian patent applications as well as 66 peer-reviewed and published research articles and abstracts and 29 presentations.
He was awarded the Strategic Training in Allergy Research Award from the American Academy of Allergy, Asthma & Immunology’s, Grant Writing Workshop that was sponsored by National Institutes of Health, The Canadian Foundation for Pharmacy National Award, Manitoba Health Research Council Award, Manitoba Institute of Child Health Award, Manitoba Pharmaceutical Association Award, Ebla Private University recognition, and NSU extramural funding recognition.
Qalaji and his team developed novel formulation of fast disintegrating sublingual tablet of epinephrine for the treatment of anaphylaxis. The Pre-IND has been reviewed favorably by the U.S. Food and Drug Administration. His novel sublingual epinephrine tablet was recently licensed through NSU—the first license for NSU and the second license for Qalaji.
Currently, he is working on developing another novel formulation for the non-invasive sublingual delivery of atropine for various clinical indications.
Join the INIM for Qalaji’s lecture,“Organophosphates Toxicities and Potential Alternative Route for Atropine Administration.” You won’t want to miss it.
RSVP is required by email to mf1184@nova.edu.